Table 4.

NAC treatment may decrease plasma Trx

Variables	Standard least squares model fit for plasma Trx at the end of the 8-week trial* (subjects with CD4 T cell counts below 200/μl)
	P (variables)	Adjusted mean plasma Trx		Adjusted R2	P (model)
		NAC	Placebo
Trial arm	0.05†	12	17	0.3	0.05
Baseline Trx	0.01
CD4 T cell count‡	0.5

^*Subjects were treated with NAC (approx 7 g/day) or placebo during an 8-week double-blind trial. The complete Trx and GSH measurements (at 0 and 8 weeks) required for this analysis were available for a total of 24 trial subjects. Two outliers (1 from each arm) were excluded from this analysis on the basis of standard statistical criteria; one questionable admission to the trial was also removed, leaving a total of 21 subjects. 

^† Power analysis indicates that trial arm would be significant at the 0.01 level if data for 36 comparable subjects, rather than the 21 studied here, were available. 

^‡ Above or below 100/μl blood.